Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032
Overview
The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is expected to reach a 11.56 USD Million by 2032 and is projected to grow at a CAGR of 7.89% from 2025 to 2032.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market 2018-2032 USD Million
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 6.32 USD Million
- Projected Market Size (2032): 11.56 USD Million
- CAGR (2025-2032): 7.89%
Key Findings of Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market
- The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market was valued at 6.32 USD Million in 2024.
- The Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market is likely to grow at a CAGR of 7.89% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Oncology in Therapeutic Application Segment accounted for the largest share of the market with a revenue of 4.87 USD Million
- The fastest growing segment Small Molecule Ligands in Vector Type Segment grew Fastest with a CAGR of 8.47% during the forecast period from 2024 to 2032.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope
- Alpha Emitters
- Beta Emitters
- Others
- Monoclonal Antibodies
- Peptides
- Small Molecule Ligands
- Research Institutes
- Radiopharmacies
- Hospitals
- Others
- Oncology
- Others
- Generator-Produced Isotopes
- Reactor-Produced Isotopes
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2024 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 6.32 USD Million |
| Market Value in 2032 | 11.56 USD Million |
| CAGR (2025-2032) | 7.89% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Isotope,Vector Type,End User,Therapeutic Application,Sources |
Regional Insights:
-
Leading Market (2024-2032): Netherlands, leading in terms of revenue 6.32 USD Million in 2024
- Key Country: Netherlands, leading in terms of revenue with value of 6.32 USD Million in 2024.
Segments and Scope
-
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Isotope
- Beta Emitters is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.63 USD Million in the year 2024.
- Beta Emitters is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.05 % in forecast period 2025-2032.
-
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Vector Type
- Small Molecule Ligands is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.29 USD Million in the year 2024.
- Small Molecule Ligands is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.47 % in forecast period 2025-2032.
-
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By End User
- Hospitals is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.61 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.02 % in forecast period 2025-2032.
-
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Therapeutic Application
- Oncology is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 4.87 USD Million in the year 2024.
- Oncology is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.22 % in forecast period 2025-2032.
-
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032, By Sources
- Reactor-Produced Isotopes is the largest segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a revenue of 3.93 USD Million in the year 2024.
- Reactor-Produced Isotopes is the Fastest growing segment in Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market to 2032 with a Growth rate of 8.02 % in forecast period 2025-2032.
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Share Analysis
| Company Name |
|
||
| Novartis AG | |||
| Eckert & Ziegler | |||
| ITM Isotope Technologies Munich SE | |||
| SHINE Technologies, LLC | |||
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Geographical Sales Distribution, 2018-2032 USD Million
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Industry Related Reports
Frequently Asked Questions
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope
- Alpha Emitters
- Beta Emitters
- Others
- Monoclonal Antibodies
- Peptides
- Small Molecule Ligands
- Research Institutes
- Radiopharmacies
- Hospitals
- Others
- Oncology
- Others
- Generator-Produced Isotopes
- Reactor-Produced Isotopes
Frequently Asked Questions
Netherlands Alpha and Beta Emitters Based Radiopharmaceuticals Market Company Profiling
Frequently Asked Questions
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.